Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced that dr. Alain Sewer, Phillip Morris
International, R&D, Neuchatel, Switzerland, has presented data from a
comprehensive validation study of the miRCURY LNA™ microRNA Array product line.

Dr. Sewer's data demonstrate that the LNA™-enhanced capture probes secure very
sensitive and specific detection of microRNAs in complex samples. The study
concludes that Exiqon's miRCURY LNA™ microRNA Array platform outperforms
similar products provided by a main competitor.

Exiqon's microRNA arrays feature Tm-normalized, LNA™-enhanced capture probes,
designed by advanced bioinformatics algorithms for excellent specificity and
sensitivity for all microRNAs in more than 100 different species.

The miRCURY LNA™ microRNA Array product line includes the miRCURY LNA™ microRNA
Arrays, miRCURY LNA™ microRNA Power Labeling Kits and the miRCURY LNA™ microRNA
Array Analysis Software. The products are provided with protocols for a number
of different instrument platforms.

”We are always pleased when a major international customer publishes the
conclusions from their internal validation studies. In this publication, it is
demonstrated that Exiqon's products are superior in terms of sensitivity and
specificity which represent the most important values for our customers”, said
Henrik M. Pfundheller, VP Sales & Marketing at Exiqon.

Additional information:
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090
2106)

See the full release in the attached PDF.

pressrelease_exiqonarray_philipmorris_final_101101.pdf